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Abstract
Background: Studies in animals and humans clearly indicate a role for prolactin (PRL) in breast
epithelial proliferation, differentiation, and tumorigenesis. Prospective epidemiological studies have
also shown that women with higher circulating PRL levels have an increase in risk of breast cancer,
suggesting that variability in PRL may also be important in determining a woman's risk.
Methods: We evaluated genetic variation in the PRL and PRL receptor (PRLR) genes as predictors
of plasma PRL levels and breast cancer risk among African-American, Native Hawaiian, Japanese-
American, Latina, and White women in the Multiethnic Cohort Study (MEC). We selected single
nucleotide polymorphisms (SNPs) from both the public (dbSNP) and private (Celera) databases to
construct high density SNP maps that included up to 20 kilobases (kb) upstream of the transcription
initiation site and 10 kb downstream of the last exon of each gene, for a total coverage of 59 kb in
PRL and 210 kb in PRLR. We genotyped 80 SNPs in PRL and 173 SNPs in PRLR in a multiethnic
panel of 349 unaffected subjects to characterize linkage disequilibrium (LD) and haplotype patterns.
We sequenced the coding regions of PRL and PRLR in 95 advanced breast cancer cases (19 of each
racial/ethnic group) to uncover putative functional variation. A total of 33 and 60 haplotype "tag"
SNPs (tagSNPs) that allowed for high predictability (Rh
2 ≥ 0.70) of the common haplotypes in PRL
and PRLR, respectively, were then genotyped in a multiethnic breast cancer case-control study of
1,615 invasive breast cancer cases and 1,962 controls in the MEC. We also assessed the association
of common genetic variation with circulating PRL levels in 362 postmenopausal controls without a
history of hormone therapy use at blood draw. Because of the large number of comparisons being
performed we used a relatively stringent type I error criteria (p < 0.0005) for evaluating the
Published: 1 December 2007
BMC Medical Genetics 2007, 8:72 doi:10.1186/1471-2350-8-72
Received: 8 June 2007
Accepted: 1 December 2007
This article is available from: http://www.biomedcentral.com/1471-2350/8/72
© 2007 Lee et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
Page 2 of 14
(page number not for citation purposes)
significance of any single association to correct for performing approximately 100 independent
tests, close to the number of tagSNPs genotyped for both genes.
Results: We observed no significant associations between PRL and PRLR haplotypes or individual
SNPs in relation to breast cancer risk. A nominally significant association was noted between
prolactin levels and a tagSNP (tagSNP 44, rs2244502) in intron 1 of PRL. This SNP showed
approximately a 50% increase in levels between minor allele homozygotes vs. major allele
homozygotes. However, this association was not significant (p = 0.002) using our type I error
criteria to correct for multiple testing, nor was this SNP associated with breast cancer risk (p =
0.58).
Conclusion: In this comprehensive analysis covering 59 kb of the PRL locus and 210 kb of the
PRLR locus, we found no significant association between common variation in these candidate
genes and breast cancer risk or plasma PRL levels. The LD characterization of PRL and PRLR in this
multiethnic population provide a framework for studying these genes in relation to other disease
outcomes that have been associated with PRL, as well as for larger studies of plasma PRL levels.
Background
Prolactin (PRL) is an essential regulator of mammary
development, acting synergistically with a wide variety of
hormones during puberty and pregnancy [1,2]. Early stud-
ies in animals first demonstrated that prolactin could
induce spontaneous mammary tumors [3-6]. Results from
in vitro studies support the findings from animal studies
and suggest that PRL stimulates proliferation, [7-10]
increases cell motility and cytoskeleton alterations [11],
and promotes angiogenesis [12] in human breast cells.
Prolactin receptor (PRLR), found in both normal and
malignant breast tissue, has been reported to be slightly
more prevalent in malignant tissue [13]. Though early
clinical studies of patients treated with bromocriptine, an
inhibitor of pituitary PRL, found no association with
breast cancer, recent evidence of autocrine/paracrine regu-
lation [14,15] of PRL in extra-pituitary tissue provides fur-
ther support for a possible role of PRL in tumorigenesis.
There are few prospective epidemiological studies evaluat-
ing plasma PRL levels and breast cancer risk. The largest
prospective cohort study of postmenopausal women
reported a 34% increase in risk of breast cancer when
comparing top to bottom quartiles (> 12 vs. < 7.4 ng/mL)
of PRL levels [16]; these findings were similar to results
from an earlier study reporting a non-significant increase
in risk of 1.34, based on a smaller sample size [17]. Two
smaller studies of postmenopausal women also reported
a positive association, but these were also non-significant
[18,19]. Results from case-control studies [20-27] give
conflicting results and are difficult to interpret due to the
retrospective nature of blood collection. There have been
limited prospective data on prolactin levels and breast
cancer risk among premenopausal women [18,19,28]
until recently; the Nurses' Health Study reported a non-
significant 30% increase in breast cancer risk among pre-
menopausal women when comparing top to bottom
quartiles (> 17.6 vs. < 9.8 ng/mL) of PRL levels among 377
cases and 786 controls [29].
In humans, the PRL gene lies on chromosome 6 and is
approximately 10 kilobases (kb) in length with five cod-
ing exons [30]. An additional non-coding first exon has
been described that lies 5.8 kb upstream of the pituitary
promoter site [31]. This distal promoter region has been
associated with extra-pituitary expression of PRL,
described in a variety of tissues including decidua, lym-
phocytes, and breast tissue. Depending on promoter
usage, PRL mRNAs may differ slightly in length but
encode the same mature polypeptide protein hormone
[32].
The human PRLR gene is located on chromosome 5 and is
approximately 180 kb in length and is originally
described as having 10 exons, of which exons 3–10 are
coding exons [33]. Recently, six alternative non-coding
first exons have been described whose functions are
unknown but have been found to be expressed in human
ovary, testis, liver, breast tissue, and breast cells [34,35]. In
addition, an exon 11 located 15 kb downstream of exon
10 has been reported; alternative splicing of exons 10 and
11 appear to produce novel short forms of the receptor
that may be involved in distinct signaling pathways than
the common long form [36,37].
Previous studies have demonstrated that genetic polymor-
phisms in candidate genes can lead to variations in
plasma levels of encoded proteins [38,39]. In this study,
we used a combination of approaches that included
sequencing the coding regions to identify common mis-
sense variation, and haplotype-based analyses to charac-
terize common patterns of genetic variation across each
locus to test the hypothesis that genetic variations in PRL
and PRLR are associated with plasma PRL levels andBMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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breast cancer risk. Tests of association were performed in
a large case-control study of breast cancer among African-
American (AA), Native Hawaiian (NH), Japanese-Ameri-
can (JA), Latina (LA), and White (WH) women in the pro-
spective Multiethnic Cohort Study (MEC). To our
knowledge, this is the first comprehensive study of com-
mon genetic variation in PRL and PRLR genes in relation
to breast cancer risk and plasma PRL levels in a multieth-
nic population
Results
Characterization of Genetic Variation at PRL and PRLR 
loci
We genotyped 80 SNPs in PRL and 173 SNPs in PRLR
(approximately 1 SNP every 1 kb) to characterize linkage
disequilibrium (LD) and haplotype patterns in a multi-
ethnic panel of 349 unaffected subjects (69–70 of each of
the 5 racial/ethnic populations in the MEC). We charac-
terized genetic variation across 59 kb of the PRL locus, 24
kb upstream of PRL's alternative first exon 1a (5.8 kb
upstream of pituitary promoter site) to 20 kb downstream
of exon 5, using 80 common (minor allele frequency,
MAF, ≥ 5%) SNPs (Additional File 1, Table S1). In PRL, we
observed three regions of LD (blocks 1, 3, 4, see the Meth-
ods section for a description of the criteria used to define
LD block regions), and one 19 kb region ("pseudo-block
2") with little evidence of LD. Based on the dense coverage
across this 19 kb region (1 common SNP every < 1 kb
apart, on average), we decided to construct haplotypes to
test associations with common variation (Figure 1, Addi-
tional File 1, Table S1). In this region, the multivariate
squared correlation, Rs
2, between the selected tagSNPs
and all SNPs examined in the multiethnic panel was =
0.70 in all ethnic groups, which suggests that unmeasured
SNPs in this region are most likely well predicted by our
set of tags. Thus, we describe four regions in PRL: block 1
(SNPs 1–24; 14 kb), "block" 2 (SNPs 25–45; 19 kb), block
3 (SNPs 46–59; 7 kb), and block 4 (SNPs 61–77; 14 kb).
In general, block sizes in PRL were similar among racial/
ethnic groups (Additional Files 2, 3, 4, 5, 6).
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for all racial/ethnic groups combined Figure 1
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for all racial/ethnic groups combined. The horizontal black 
line depicts the 59-kilobase region of chromosome (chr) 6 analyzed in our multiethnic panel. The PRL gene is shown in grey 
(RefSeq gene = completed genes from the human genome assembly). Alternative exon 1a (associated with the distal extra-pitu-
itary promoter region) lies 5.8 kb upstream of exon 1 (associated with the pituitary promoter region). The 80 single nucleotide 
polymorphisms (SNPs) used for genetic characterization are listed below the black line. The LD plot, presented at the bottom 
of the figures, is based on the measure of D'. Each diamond indicates the pairwise magnitude of LD, with dark grey indicating 
strong LD (D' > 0.8) and a logarithm of odds score of greater than 2.0. (Figure prepared with LocusView, Broad Institute, Cam-
bridge, MA, unpublished software by T. Petryshen, A. Kirby, and M. Ainscow [61]).BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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In PRLR, we assessed 210 kb of the locus, from 25 kb
upstream of the first alternative exon E13 to 10 kb down-
stream of exon 11 (the alternatively spliced exon 10)
(Additional File 1, Table S2). Using 173 common SNPs,
we defined nine blocks of LD in PRLR: block 1 (SNPs
6–30; 14 kb), block 2 (SNPs 31–39; 10 kb), block 3 (SNPs
41–66; 29 kb), block 4 (SNPs 73–88; 22 kb), block 5
(SNPs 95–113; 31 kb), block 6 (SNPs 114–135; 35 kb),
block 7 (SNPs 136–153; 24 kb), block 8 (SNPs 154–161;
3 kb), and block 9 (SNPs 167–173; 6 kb) (Figure 2, Addi-
tional File 1, Table S2). Compared to the other racial/eth-
nic groups, African-Americans demonstrated smaller
block sizes for block 3 (SNPs 49–58), block 5 (SNPs
102–113), block 6 (SNPs 114–124), and block 7 (SNPs
147–153), and Native Hawaiians had larger block sizes,
with combined blocks 1–3 (SNPs 1–72) and blocks 5–9
(SNPs 97–173) (Additional Files 7, 8, 9, 10, 11). "Tag-
ging" SNPs (tagSNPs) were selected to allow for high pre-
dictability of the common haplotypes (= 5% frequency in
any one ethnic population) with LD blocks in both genes:
33 tagSNPs in PRL and 60 tagSNPs in PRLR (Additional
File 1, Tables S1 and S2; see Methods for a description of
the approach utilized to select tagSNPs). African-Ameri-
cans demonstrated a greater number of common haplo-
types per block (Additional File 1, Table S9). Therefore, in
order to accurately predict the common haplotypes in
PRLR for African-Americans, additional tagSNPs were
genotyped for blocks 1, 2, 3, 5, 7, and 9 (tagSNPs 16, 24,
35, 49, 111, 112, 151, 153, 167, and 171).
Of the 60 tagSNPs selected in PRLR we were unable to
genotype four of them in the case-control study because
Illumina assays could not be designed, block 1: SNP6
(rs9986182), SNP12 (rs9292582), SNP24 (rs6451192),
and SNP29 (rs7701473). This resulted in the inability to
distinguish between haplotypes 1A1, 1A2, and 1A3 in LA
(minor allele frequency 16.9%, 6.4%, and 6.6%),
between haplotypes 1A1 and 1A3 in AA (9.2% and 2.2%),
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) locus for all racial/ethnic groups combined Figure 2
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) locus for all racial/ethnic groups combined. The horizon-
tal black line depicts the 210-kilobase region of chromosome (chr) 5 analyzed in our multiethnic panel. The PRLR gene is 
shown in grey (RefSeq gene = completed genes from the human genome assembly). Alternative first exons are shown in black 
below the gene: hE13, hE1N1, hE1N2, hE1N3, hE1N4, and hE1N5. The 173 single nucleotide polymorphisms (SNPs) used for 
genetic characterization are listed below the black line. The LD plot, presented at the bottom of the figures, is based on the 
measure of D'. Each diamond indicates the pairwise magnitude of LD, with dark grey indicating strong LD (D' > 0.8) and a loga-
rithm of odds score of greater than 2.0. (Figure prepared with LocusView, Broad Institute, Cambridge, MA, unpublished soft-
ware by T. Petryshen, A. Kirby, and M. Ainscow [61]).BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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and between 1A1 and 1A2 in NH (17.2% and 4.5%) and
in WH (34.6% and 5.9%) (Additional File 1, Table S9)
which spans 14.2 kb, 142 kb upstream of the start codon
in exon 3. Aside from block 1 of PRLR, the predicted com-
mon haplotypes frequencies in the multiethnic panel
were similar to those observed in the larger case-control
sample (Additional File 1, Tables S8-S11). Therefore, only
haplotypes with ≥ 5% frequency in cases or controls, per
each racial/ethnic group, are shown in Additional File 1,
Tables S10 and S11. To assess how well the selected tag-
SNP perform in capturing the common SNPs that were
not selected as tagSNPs in each population, we calculated
multi-marker R2 measures for both genes [40]. For PRL,
the fraction of SNPs predicted with a multi-marker R2 >
0.7 was 89%, 93%, 98%, 100%, and 100% for AA, NH, JA,
LA, and WH, respectively. For PRLR (even without the
four tagSNPs), the fraction of SNPs captured with multi-
marker R2 > 0.7 was 84%, 92%, 90%, 92%, and 93%.
Thus, the selected tagSNPs capture most of the SNPs eval-
uated in the LD characterization phase, and based on
high-density SNPs coverage in this study (1 SNPs every ~1
kb, on average), we expect these tags to also predict the
vast majority of all common alleles in these genes.
We sequenced the exons and splice-site regions of PRL
and PRLR in germline DNA from 95 advanced breast can-
cer cases (19 of each racial/ethnic group). PRL and PRLR
sequencing confirmed only one missense SNP, Ile100Val
(rs16871473) in exon 5 of PRLR. The SNP was observed
most commonly among Native Hawaiians (MAFs, 11%,
15%, 5%, 1%, and 2% in AA, NH, JA, LA, and WH, respec-
tively) (Additional File 1, Table S2). A previously reported
missense SNP in exon 6 of PRLR (Ile170Leu) was mono-
morphic in all ethnic groups [41]. For PRL, we discovered
a low frequency synonymous SNP in exon 3
(A+444152G). We were also able to validate a previously
reported synonymous SNP in exon 5 (rs6239), but not a
synonymous SNP in exon 2 (rs6240) or a missense SNP in
exon 4 (rs6238) (Additional File 1, Table S1).
Case-control analysis
The distribution of breast cancer risk factors among the
1,615 breast cancer cases and 1,962 controls were consist-
ent with the patterns observed in the overall cohort, and
have been previously published [42] (Additional File 1,
Table S3). We tested the independent effects of each tag-
SNP for PRL and PRLR in the case-control population
(Additional File 1, Tables S4 and S5). Odds ratios (ORs)
and 95% confidence intervals (CIs) were estimated for
each tagSNP using unconditional logistic regression
adjusted for age and ethnicity (co-dominant effects are
reported in the manuscript, detailed genotype-specific
effects are shown in the tables). Because of the large
number of comparisons being performed, we used a rela-
tively stringent type I error criteria (p < 0.0005) for evalu-
ating the significance of any single association. (This
"corrects" for performing approximately 100 independent
tests, close to the number of tagSNPs genotyped for both
genes). The strongest associations between individual
SNPs and breast cancer risk were with SNP34 (rs9466314)
in "block 2" of PRL (co-dominant effect OR, 1.48; 95% CI,
1.00–2.18; p = 0.049) and SNP49 (rs34024951) in block
3 of PRLR (co-dominant effect OR, 0.85; 95% CI,
0.73–0.99; p = 0.032) (Table 1). Of note, SNP34 in PRL
was only observed among AAs, with a MAF of 6% in cases
and 5% in controls in our sample. The missense Ile100Val
SNP in PRLR was not associated with breast cancer risk
Table 1: Nominally significant associations between prolactin (PRL) and prolactin receptor (PRLR) tagSNPs and breast cancer risk
SNP AA NH JA LA WH OR (95%CI)a
% 
cases
% 
controls
% 
cases
% 
controls
% 
cases
% 
controls
% 
cases
% 
controls
% 
cases
% 
controls
PRL
"BLOCK 2"
SNP 34 (rs9466314)
AA 85.96 90.80 99.07 100.00 100.00 100.00 97.90 98.44 100.00 99.54 ref
AT 13.45 8.73 0.93 0.00 0.00 0.00 2.10 1.56 0.00 0.46 1.54 (1.02–2.34)
TT 0.58 0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 (0.18–9.22)
PRLR P trend = 0.049
BLOCK 3
SNP 49 (rs34024951)
CC 51.63 46.57 93.4 88.97 86.76 86.19 84.34 83.77 84.96 84.02 ref
CT 43.03 42.79 6.60 11.03 12.77 13.81 15.06 15.18 14.79 15.30 0.92 (0.77–1.10)
TT 5.34 10.64 0.00 0.00 0.47 0.00 0.60 1.05 0.25 0.68 0.50 (0.30–0.83)
P trend = 0.032
AA, African Americans; NH, Native Hawaiians; JA, Japanese Americans; LA, Latinas, WH, Whites.
a ORs adjusted for age and ethnicity.
b P-value for test of trend.BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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(co-dominant effect OR, 1.02; 95%CI, 0.83–1.24; p =
0.883) (Additional File 1, Table S5).
We performed haplotype analyses using the most com-
mon haplotype as the reference group (Additional File 1,
Tables S10 and S11); results were similar when we used all
other haplotypes as the reference group (data not shown).
In the analysis of the common haplotypes, haplotype 3I
of PRL was nominally associated with risk (OR, 1.27;
95%CI, 1.02–1.59; p = 0.036) (Additional File 1, Table
S10). This haplotype was only common in NH (14%) and
JA (18%), and the effect was observed only in JA (OR,
1.39; 95%CI, 1.07–1.81; p = 0.015; p-heterogeneity =
0.193). No haplotypes in PRL or PRLR haplotypes were
significantly associated with breast cancer risk using our
type I error criteria (p < 0.0005) (Additional File 1, Tables
S10 and S11).
Plasma prolactin level analysis
Among the 362 postmenopausal controls in the biomar-
ker analysis, the median plasma PRL level was 8.1 ng/mL.
Prolactin levels did not vary by race/ethnicity, before or
after adjusting for potential confounders: parity, age at
first pregnancy, body mass index, family history of breast
cancer, and menopause age and type (p-heterogeneity =
0.447) (data not shown). The strongest association
between a single SNP and PRL levels was with SNP44
(rs2244502) of PRL, which showed approximately a 50%
increase in levels between minor allele homozygotes ver-
sus major allele homozygotes (Additional File 1, Tables
S6 and S7). We also observed nominally significant asso-
ciations between prolactin levels and seven SNPs in PRL
(SNP33, SNP34, SNP39, SNP44, SNP54, SNP62, SNP65)
and two SNPs (SNP73, SNP148) in PRLR (Table 2). None
of these associations were significant at the p < 0.0005
level.
Table 2: Nominally significant associations between prolactin (PRL) and prolactin receptor (PRLR) tagSNPs and plasma PRL levels
SNP SNP Name N (%) Genotype LS meansa (95% CI) pb
PRL
"BLOCK" 2
SNP 33 rs1341238 167 (64.98) GG 7.15 (6.35 – 8.06) 0.025
65 (25.29) AG 9.23 (7.68 – 11.09)
25 (9.73) AA 9.02 (6.69 – 12.16)
SNP 34 rs9466314 248 (96.50) AA 7.67 (6.94 – 8.49) 0.039
8 (3.11) AT 10.48 (6.25 – 17.58)
1 (0.39) TT 31.75 (7.69 – 131.02)
SNP 39 rs3756824 246 (81.19) CC 7.56 (6.86 – 8.34) 0.035
56 (18.48) CG 9.73 (8.00 – 11.82)
1 (0.33) GG 6.15 (1.55 – 24.49)
SNP 44 rs2244502 145 (47.85) AA 6.96 (6.15 – 7.88) 0.002
126 (41.58) AT 8.64 (7.60 – 9.82)
32 (10.56) TT 10.30 (7.91 – 13.41)
BLOCK 3
SNP 54 rs849886 83 (25.54) CC 9.33 (7.83 – 11.13) 0.048
157 (48.31) CT 8.22 (7.31 – 9.24)
85 (26.15) TT 7.27 (6.15 – 8.59)
BLOCK 4
SNP 62 rs849870 191 (64.09) CC 8.72 (7.81 – 9.72) 0.013
96 (32.21) CT 7.28 (6.30 – 8.41)
11 (3.69) TT 5.66 (3.69 – 8.70)
SNP 65 rs849872 142 (47.65) TT 8.96 (7.92 – 10.14) 0.018
123 (41.28) CT 7.47 (6.59 – 8.48)
33 (11.07) CC 6.93 (5.42 – 8.85)
PRLR
BLOCK 4
SNP 73 rs10941235 135 (49.45) CC 8.97 (7.78 – 10.33) 0.042
107 (39.19) CT 7.09 (6.13 – 8.20)
SNP 148 rs37364 136 (49.1) TT 7.34 (6.44 – 8.35) 0.037
106 (38.27) GT 8.49 (7.32 – 9.86)
35 (12.64) GG 9.72 (7.50 – 12.6)
AA, African Americans; NH, Native Hawaiians; JA, Japanese Americans; LA, Latinas, WH, Whites.
a Least square means of prolactin levels and 95% confidence interval; LS means adjusted for age, ethnicity, and assay batch.
b P-value for test of trend.BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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Discussion
We genotyped a high density of SNPs to characterize the
haplotype structure of PRL and PRLR genes, using the cri-
terion for haplotype-based studies described by Gabriel et
al. [43] and the multivariate Rh
2 statistic [44] to provide
high predictability of the common haplotypes in PRL and
PRLR. We found that in almost all ethnic groups and for
both genes, the selected tagSNPs performed well in pre-
dicting the common SNPs typed in the LD characteriza-
tion phase (average multi-marker R2  = 0.95) and the
common haplotypes defined by the tagSNPs (average
minimum Rh
2 = 0.87).
Assuming an average multi-marker R2 = 0.90 between
causal alleles and tagSNPs or haplotype predictors, we
had 96% power to detect relative risks of 1.29 per haplo-
type or genotype copy with 10% frequency, allowing for a
5% type I error rate. However, given the large number of
statistical tests for each gene, we expected several false pos-
itive associations. By a more stringent type I error criteria
(p < 0.0005) the detectable relative risk, at 90% power, for
a dominant allele with 10% frequency, is 1.45 per copy.
By ethnic group, we had 78–82% power to detect large
ORs ≥ 2.1 (except in NH, ORs ≥ 3.0) with this significance
level. The purpose of this study however, was to assess
shared common genetic variation across ethnic groups.
For PRL levels among 362 controls, only fairly large differ-
ences in mean levels could be detected with good power.
For example, after correcting for 100 comparisons (e.g.
using p < 0.0005), we estimate that we had 90% power to
detect an association between PRL levels and a common
(10%) variant only when that variant was associated with
approximately a 50% change in mean levels per genotype/
haplotype copy.
A recent German study of 441 cases and 552 controls
reported an increase in breast cancer risk associated with
genetic variation in PRL: rs1341239 (SNP35) (OR, 1.67;
95%CI, 1.11–2.50 for homozygous individuals) and
rs12210179 (OR, 2.09; 95%CI, 1.23–3.52), which we did
not genotype in our sample. SNP35 has been shown to be
functionally significant in relation to Systemic Lupus Ery-
thematosus (SLE) [45,46]. Vaclavicek et al. reported that
rs12210179 does not lie within any transcription binding
site and is in high LD (|D'| = 0.91) with SNP35 [47].
Among Whites in the MEC, SNP35 is well predicted by
tagSNP33, pairwise R2 = 0.86. Using HapMap data [48],
rs12210179 is common (27%) among Caucasians (vs.
Yorubans 4%, Japanese 1%) and for Caucasians, is well
predicted by tagSNP43 (pairwise R2 = 1.00). Though we
did not test these SNPs directly in our study, using these
"surrogate" tagSNPs, we did not find any significant asso-
ciation with breast cancer risk among Whites (tagSNP33:
OR 0.96; 95%CI, 0.80–1.16, p = 0.705; tagSNP43: OR
0.98; 95%CI, 0.78–1.23, p = 0.879) or overall (tagSNP33:
OR 1.03; 95%CI, 0.93–1.14, p = 0.584; tagSNP43: OR
1.07; 95%CI, 0.93–1.22, p = 0.346).
Vaclavicek et al. also reported a TGTG haplotype in PRL
comprised of rs1341239 (SNP35), rs12210179 (not gen-
otyped in our sample), rs2244502 (tagSNP44), and
rs1205960 (tagSNP56) associated with breast cancer risk
(OR, 1.42; 95%CI, 1.07 – 1.90) [47]. This haplotype falls
in "block" 2 and block 3 of our characterization of the PRL
locus (Additional File 1, Table S1). Using 11 tagSNPs for
"block 2" (multi-marker R2 = 0.79–1.00 for Whites) and 7
tagSNPs for block 3 (multi-marker R2 = 0.92–1.00 for
Whites), we did not observe an association with breast
cancer risk (Additional File 1, Table S10). We used "surro-
gate" tagSNPs 33, 43, 44, and 56 to best approximate the
TGTG haplotype but did not observe an association
between common surrogate haplotypes and breast cancer
risk among Whites (global test p = 0.78) or overall (global
test p = 0.70). Further studies are needed to directly eval-
uate the TGTG haplotype in relation to breast cancer risk,
especially among Whites.
We found that tagSNP34 (2.1 kb upstream of SNP35 in
the promoter region of PRL) had the strongest association
with risk of breast cancer (p = 0.049). It is possible that
this SNP may be functionally significant as both SNP34
and SNP35 lie in the distal extra-pituitary promoter
region of prolactin. However, this SNP was only observed
among AAs, with a minor allele frequency (MAF) of 6% in
cases and 5% in controls in our sample. Further studies
are needed to assess the relevance of this finding. The
strongest association in PRL between a haplotype and
breast cancer risk was with haplotype 3I in block 3 (p =
0.036). This haplotype was only observed in JA and NH,
and the association with risk was confined to JA.
For PRLR, the only missense SNP previously described in
relation to breast cancer risk is a Leu150Ile SNP in exon 6
which was reported in 2 of 38 cases in a Turkish study
[41]. In our large sample, this SNP was monomorphic;
however, it is possible that it is rare or only observed in
certain populations.
Vaclavicek et al. also reported a protective TCC haplotype
in PRLR (OR, 0.69; 95%CI, 0.54–0.89; p = 0.004) using
just three tagSNPs. The TCC haplotype consists of
rs13354826 (not genotyped in our sample, block 2),
rs9292573 (SNP59, block 3), and rs37389 (SNP141,
block 7). In Whites, these SNPs are well predicted:
rs13354826 (tagSNPs 7 and 35, HapMap data, multi-
marker R2 = 1.00), SNP59 (tagSNP55, pairwise R2 = 1.00),
and SNP141 (tagSNP139, pairwise R2 = 0.94). We used
"surrogate" tagSNPs 7, 35, 55, and 139 to approximate the
TCC haplotype and found that the common haplotypes
comprised of these surrogate SNPs were not significantlyBMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
Page 8 of 14
(page number not for citation purposes)
associated with risk. Though we are unable to form a
direct prediction of the TCC haplotype, we believe that
our approach is comprehensive enough to have detected
a true association within this region of the strength
reported by Vaclavicek et al. Using 56 tagSNPs across high
density coverage of 210 kb of the PRLR locus (25 kb
upstream of first alternative exon E13 t o  1 0  k b  d o w n -
stream of exon 11), we did not find an association
between SNPs or haplotypes in PRLR and breast cancer
risk.
We did not generate convincing evidence of an associa-
tion between PRL levels and common genetic variation in
PRL and PRLR, although our study was limited by small
sample size. The most significant p-value was 0.002 for
SNP44 in PRL, which corresponds to a 48% increase in
PRL levels between major and minor allele homozygotes.
The Nurses Health Study [16] demonstrated that > 1.6-
fold difference between upper and lower quartiles of PRL
levels was associated with a 34% increase in breast cancer
risk. We did not observe an association between breast
cancer risk and SNP44 (p = 0.575). However, even if the
association between SNP44 and prolactin levels were cor-
rect, and assuming a direct influence of genetically deter-
mined prolactin levels on breast cancer risk consistent
with the Nurses Health Study, the 48% increase in PRL
levels for minor allele homozygotes of SNP44 would still
only correspond to a 10% risk increase between carriers
and non-carriers of two copies. Such an increase in risk is
not detectable in this study with reasonable power, which
could explain the apparent lack of association between
SNP44 and breast cancer risk in this study. Further studies
in larger samples are needed to definitively assess the rela-
tionship between this polymorphism, plasma PRL levels
and breast cancer. In addition, our results may not be gen-
eralizable to premenopausal women since we only
included postmenopausal women in our analysis. Prolac-
tin levels have been shown to decline slightly among post-
menopausal women compared to premenopausal women
[2]. However, the NHS study evaluated prolactin levels
among premenopausal and postmenopausal women and
found no difference in risk of breast cancer by menopau-
sal status: premenopausal (RR 1.3, 95% CI 0.9–1.9) vs.
postmenopausal (RR 1.3, 95% CI 1.0–1.8) women
[16,29]. It is unclear whether we could draw similar con-
clusions from our study population.
Strengths of this study include the large case-control sam-
ple size, comprehensive assessment of LD block structure,
and tagSNP selection providing excellent prediction of
nearly all SNPs or common haplotypes, across five racial/
ethnic populations. However, the ability to definitively
evaluate ethnic-specific risks and associations with
plasma PRL levels should be interpreted with caution, due
to the small number of subjects in these groups. Further
studies using larger samples of PRL levels are needed to
assess the relationship with polymorphisms in the PRL
and PRLR genes, and in particular, to validate the associa-
tion observed between PRL levels and SNP44 in PRL.
Conclusion
This the largest and most comprehensive study of com-
mon genetic variation in PRL pathway genes in relation to
breast cancer risk and plasma PRL levels. In contrast to a
recent study of PRL and PRLR in relation to breast cancer,
we observed no strongly significant associations with
breast cancer risk. We also did not find an association
between common genetic variation in PRL or PRLR and
circulating plasma PRL levels. Our results emphasize the
importance of using high density genotyping to ade-
quately characterize genes for use in association studies
and caution against false positive results when interpret-
ing these data. Though we did not observe an association
with breast cancer risk, results from our study provide a
framework for future association studies of PRL pathway
genes in relation to other diseases (such as Systemic Lupus
Erythematosus) and for larger studies of plasma PRL lev-
els.
Methods
Subjects
The MEC consists of over 215,000 men and women in
Hawaii and Los Angeles (with additional African-Ameri-
cans from elsewhere in California) and has been previ-
ously described in detail [49]. The cohort is mainly
comprised of five self-described racial-ethnic populations:
Native Hawaiians, Japanese-Americans and Whites from
Hawaii, and African-Americans, Japanese-Americans and
Latinos from Los Angeles. Between 1993 and 1996, partic-
ipants entered the MEC by completing a self-administered
mail questionnaire that asked detailed information about
dietary habits, demographic factors, personal behaviors,
history of prior medical conditions, family history of
common cancers, and for women, reproductive history
and exogenous hormone use. The participants were
between the ages 45 and 75 when they entered the cohort.
Incident cancers in the MEC are identified by record link-
age to the Hawaii Tumor Registry, the Cancer Surveillance
Program for Los Angeles County, and the California State
Cancer Registry. These population-based tumor registries
participate in the National Cancer Institute's Surveillance,
Epidemiology and End Results (SEER) program of cancer
registration which is known to have an excellent (98%)
case ascertainment. From the registries we also obtained
information about stage of disease at diagnosis. Breast
cancer cases were classified as "advanced" cases when
diagnosed with invasive/non-localized disease (SEER
stage ≥ 2) at diagnosis.BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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Beginning in 1996, blood samples were collected from
incident breast cancer cases. At this time, blood collection
was also initiated in a random sample of MEC partici-
pants to serve as a control pool for genetic analyses. The
participation rates for providing blood sample were ≥
65% for cases and controls. Demographic characteristics
related to socio-economic status and acculturation (e.g.
age at cohort entry, education, place of birth, and years liv-
ing in the United States) were similar among those who
provided a blood sample and women in the entire cohort.
Eligible breast cancer cases in this study consisted of
women with incident breast cancer diagnosed after enroll-
ment in the MEC through April 2002. Controls were
women without breast cancer prior to entry into the
cohort and without a cancer diagnosis up to April 2002,
and were frequency matched to cases by age and ethnicity.
Because < 6% of cohort members have moved outside of
the Hawaii and Los Angeles between enrollment
(1993–1996) and the cut-off date for diagnosis (April
2002) the likelihood of missing cases that accrued in the
cohort over this period of time is low.
The study consists of 1,615 invasive breast cancer cases
(345 African Americans, 425 Japanese Americans, 335
Latinas, 109 Native Hawaiians, and 401 Whites) and
1,962 controls. By racial/ethnic group, the number of
cases and controls were 345/426 AA, 109/290 NH, 425/
420 JA, 335/386 LA, and 401/440 WH. The study protocol
was approved by the Institutional Review Boards at the
University of Hawaii and at the University of Southern
California.
Subjects included in the analysis of plasma PRL levels
were a random sample of the controls in the case-control
panel. A total of 500 postmenopausal women with previ-
ously collected biospecimens (100 in each ethnic group)
were included. Women reporting hormone therapy use at
blood draw were excluded (n = 128), and individuals with
PRL levels that were 2.5-fold outside the normal range
were excluded (n = 10).
Gene Sequencing
We sequenced the exons and splice-site regions of PRL
and PRLR in germline DNA from 95 advanced breast can-
cer cases (19 of each racial/ethnic group). We used DNA
samples from advanced cases to increase the probability
of discovering single nucleotide polymorphisms (SNPs)
that are biologically relevant to breast cancer. Sequencing
was performed using ABI BigDye terminator chemistry on
the ABI 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA). The PolyPhred program was used to identify
polymorphisms with manual review by at least two
observers, and all putative coding variants were validated
by genotyping in the same panel of advanced cases and in
the multiethnic panel (discussed below).
Characterization of Linkage Disequilibrium and 
Haplotype Patterns
We used a haplotype-based approach to study common
variation in PRL and PRLR in the MEC, previously
described elsewhere [42]. We selected single nucleotide
polymorphisms (SNPs) from both the public (National
Center of Biotechnology Information [50]) and private
(Celera [51]) databases to construct high density SNP
maps that included up to 20 kilobases (kb) upstream of
the transcription initiation site and 10 kb downstream of
the last exon of each gene, for a total coverage of 59 kb in
PRL and 210 kb in PRLR. Block structure was assessed
using SNPs with MAF ≥ 10%. Blocks were initially defined
following alignment across racial/ethnic groups; borders
were characterized by SNPs at the extreme ends of the
block in any one ethnic group, except for African-Ameri-
cans, whose block sizes, as expected, were modestly
smaller than the other groups. We tested the suitability of
this block definition by evaluating whether SNPs sur-
rounding presumed block borders modified the number
or identity of common haplotypes estimated within the
blocks; changes in the number of haplotypes and the
introduction of recombinant haplotypes would indicate
whether SNPs were spanning a potentially important site
of historical recombination and guided us in redefining a
block boundary.
We genotyped common SNPs (MAF > 5% in at least one
racial/ethnic group) at a density of 1 SNP every ~1 kb on
average across the locus, all known missense SNPs in pub-
lic database, and all newly identified missense SNPs in
our sequencing effort. In total, 139 (PRL) and 276 (PRLR)
SNPs were selected and genotyped in a multiethnic panel
of 349 women in the MEC without a history of cancer (n
= 69–70 per racial-ethnic group). This sample size allows
> 99% power to detect common haplotypes (≥ 5% fre-
quency) that are shared across all ethnic groups, and
about 90% power to detect common ethnic-specific hap-
lotypes. Of these SNPs, 36 (PRL) and 74 (PRLR) were
identified as monomorphic and 17 (PRL) and 22 (PRLR)
genotyped poorly (SNPs missing genotype data for ≥ 25%
of samples or out of Hardy-Weinberg equilibrium more
than one of the populations, p ≤ 0.01). This left 80 (PRL)
and 173 (PRLR) SNPs with MAF = 5% in at least one
racial-ethnic group to be included in the haplotype analy-
sis.
The |D'| and r2 statistics were used to assess pairwise link-
age disequilibrium (LD) between the common SNPs.
Within regions of strong LD [43], haplotype frequency
estimates were constructed from the genotype data in the
multiethnic panel (one ethnicity at a time) using the
expectation-maximization (E-M) algorithm of Excoffier
and Slatkin [52]. The squared correlation (Rh
2) between
the true haplotypes (h) and their estimates were then cal-BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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culated as described by Stram et al.[44]. "Tagging" SNPs
(tagSNPs) for the case-control study were then chosen by
finding the minimum set of SNPs for each ethnic group
that would have Rh
2 > 0.7 for all common haplotypes with
an estimated frequency of ≥ 5%. TagSNP selection was
performed using the tagSNPs program [53].
Values of the multi-marker and pairwise R2  values
between tagSNPs and unmeasured SNPs were calculated
using the Tagger algorithm [40] in Haploview and the
slightly more general method given in Stram 2004 [54].
Genotyping
DNA for all subjects was extracted from white blood cell
fractions using the Qiagen Blood Kit (Qiagen, Chats-
worth, CA). SNP genotyping in the multiethnic panel was
performed using the Sequenom (Sequenom Inc, San
Diego, CA) platform. Tag SNP genotyping in the breast
cancer cases and controls was performed by the 5' nucle-
ase TaqMan allelic discrimination assay (ABI7900) and
the Illumina (Illumina Inc, San Diego, CA) platforms.
Replicate blinded quality control samples (5%) were
included to assess reproducibility of the genotyping pro-
cedure; the concordance was ≥ 99.7% for all platforms.
Plasma Prolactin Measurements
Prolactin was measured using a double-antibody, immu-
noradiometric assay from Diagnostic System Laboratories
(Webster, Texas) in hormone analysis laboratories at the
International Agency for Research on Cancer. The assay
was performed in multiple batches with equal numbers of
each population in each batch. The theoretic sensitivity
(as stated by the manufacturer) is 0.1 ng/ml. Mean intra-
and inter-batch coefficients of variation were 5.4% and
12.8% respectively, using 25 microliters sample volumes.
Plasma PRL levels have been shown to be stable in whole
blood for 24–48 hours [55]. In the MEC, time from blood
collection to processing was no more than six hours.
Statistical Analysis
Haplotype frequencies among breast cancer cases and
controls were estimated using the tagSNPs selected to dis-
tinguish the common haplotypes (≥ 5% frequency) for
each ethnic group in the multiethnic panel as described
[56]. The E-M algorithm was used to estimate haplotype
frequencies for the tagSNPs in the combined dataset
(cases + controls) and individual estimates of haplotype
count (expected number of copies of each haplotype car-
ried by each individual) from the E-M were outputted to
an external file and merged with case-control status. These
estimates were then used as explanatory variables in logis-
tic regression models.
As shown empirically [57], the majority of common vari-
ation is shared across racial and ethnic populations
[57,58] while the biological effects on risk for the majority
of common disease-associated alleles have also been
shown to be consistent across populations [59]. These
observations justify pooling genetic data across racial and
ethnic populations if no heterogeneity is noted. To assess
the consistency of genetic effects across populations, we
first tested for heterogeneity across racial-ethnic groups
prior to pooling genetic data. These tests were performed
using a likelihood ratio test following the inclusion of an
interaction term between the each haplotype (or SNP)
and ethnicity in the logistic regression model. Pooled
odds ratios (ORs) and 95% confidence intervals (CIs)
were then estimated for each haplotype and tagSNP using
unconditional logistic regression adjusted for age and eth-
nicity. Because of the large number of comparisons being
performed we used a relatively stringent type I error crite-
ria (p < 0.0005) for evaluating the significance of any sin-
gle association. (This "corrects" for performing
approximately 100 independent tests, close to the
number of tagSNPs genotyped for both genes).
We used the methods described by Zaykin et al. to per-
form global tests of association between haplotypes and
cancer risk within each LD block and to estimate haplo-
type-specific odds ratios [60]. ORs were estimated for each
common haplotype using the most common haplotype as
the reference group and for each SNP using the more com-
mon genotype as the reference group. We also performed
the haplotype analyses using all other haplotypes as the
reference group and performed individual SNP analyses
for co-dominant effects, both of which yielded similar
results (data not shown). Because further adjustment for
study area (Hawaii or Los Angeles) and the established
breast cancer risk factors (first-degree family history of
breast cancer, body mass index, parity, age at first birth,
age at menarche, type and age at menopause, use of hor-
mone replacement therapy, and alcohol consumption)
did not impact our results, we only present results from
the age- and ethnicity-adjusted models.
We also calculated the effect of SNPs and estimated hap-
lotypes on plasma PRL levels using generalized linear
models adjusted for continuous (age, anthropometry)
and categorical (reproductive history) variables. The hor-
mone measurements were log-transformed to best
approximate a normal distribution. These values were
transformed back to normal physiologic values for pres-
entation. Means are presented as least-squares means (LS
means). For all analyses, a dominant, co-dominant, and
recessive model were fitted.
The haplotype frequencies and counts were estimated
using tagSNPs program [53]. All other statistical analyses
were conducted using SAS version 9.1 (SAS Institute, Cary,
NC).BMC Medical Genetics 2007, 8:72 http://www.biomedcentral.com/1471-2350/8/72
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Additional file 2
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for 
African-Americans. The horizontal black line depicts the 59-kilobase 
region of chromosome (chr) 6 analyzed in our multiethnic panel. The PRL 
gene is shown in grey (RefSeq gene = completed genes from the human 
genome assembly). Alternative exon 1a (associated with the distal extra-
pituitary promoter region) lies 5.8 kb upstream of exon 1 (associated with 
the pituitary promoter region). The LD plot, presented at the bottom of the 
figures, is based on the measure of D'. Each diamond indicates the pair-
wise magnitude of LD, with dark grey indicating strong LD (D' > 0.8) 
and a logarithm of odds score of greater than 2.0. Single nucleotide poly-
morphisms (SNPs) < 5% for this ethnic group not shown. (Figure pre-
pared with LocusView, Broad Institute, Cambridge, MA, unpublished 
software by T. Petryshen, A. Kirby, and M. Ainscow [61]).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-72-S2.png]
Additional file 3
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for 
Native-Hawaiians. The horizontal black line depicts the 59-kilobase 
region of chromosome (chr) 6 analyzed in our multiethnic panel. The PRL 
gene is shown in grey (RefSeq gene = completed genes from the human 
genome assembly). Alternative exon 1a (associated with the distal extra-
pituitary promoter region) lies 5.8 kb upstream of exon 1 (associated with 
the pituitary promoter region). The LD plot, presented at the bottom of the 
figures, is based on the measure of D'. Each diamond indicates the pair-
wise magnitude of LD, with dark grey indicating strong LD (D' > 0.8) 
and a logarithm of odds score of greater than 2.0. Single nucleotide poly-
morphisms (SNPs) < 5% for this ethnic group not shown. (Figure pre-
pared with LocusView, Broad Institute, Cambridge, MA, unpublished 
software by T. Petryshen, A. Kirby, and M. Ainscow [61]).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-72-S3.png]
Additional file 4
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for Jap-
anese-Americans. The horizontal black line depicts the 59-kilobase region 
of chromosome (chr) 6 analyzed in our multiethnic panel. The PRL gene 
is shown in grey (RefSeq gene = completed genes from the human genome 
assembly). Alternative exon 1a (associated with the distal extra-pituitary 
promoter region) lies 5.8 kb upstream of exon 1 (associated with the pitu-
itary promoter region). The LD plot, presented at the bottom of the figures, 
is based on the measure of D'. Each diamond indicates the pairwise mag-
nitude of LD, with dark grey indicating strong LD (D' > 0.8) and a log-
arithm of odds score of greater than 2.0. Single nucleotide polymorphisms 
(SNPs) < 5% for this ethnic group not shown. (Figure prepared with 
LocusView, Broad Institute, Cambridge, MA, unpublished software by T. 
Petryshen, A. Kirby, and M. Ainscow [61]).
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[http://www.biomedcentral.com/content/supplementary/1471-
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Additional file 5
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for 
Latinas. The horizontal black line depicts the 59-kilobase region of chro-
mosome (chr) 6 analyzed in our multiethnic panel. The PRL gene is 
shown in grey (RefSeq gene = completed genes from the human genome 
assembly). Alternative exon 1a (associated with the distal extra-pituitary 
promoter region) lies 5.8 kb upstream of exon 1 (associated with the pitu-
itary promoter region). The LD plot, presented at the bottom of the figures, 
is based on the measure of D'. Each diamond indicates the pairwise mag-
nitude of LD, with dark grey indicating strong LD (D' > 0.8) and a log-
arithm of odds score of greater than 2.0. Single nucleotide polymorphisms 
(SNPs) < 5% for this ethnic group not shown. (Figure prepared with 
LocusView, Broad Institute, Cambridge, MA, unpublished software by T. 
Petryshen, A. Kirby, and M. Ainscow [61]).
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Additional file 6
Linkage disequilibrium (LD) plot across the prolactin (PRL) locus for 
Whites. The horizontal black line depicts the 59-kilobase region of chro-
mosome (chr) 6 analyzed in our multiethnic panel. The PRL gene is 
shown in grey (RefSeq gene = completed genes from the human genome 
assembly). Alternative exon 1a (associated with the distal extra-pituitary 
promoter region) lies 5.8 kb upstream of exon 1 (associated with the pitu-
itary promoter region). The LD plot, presented at the bottom of the figures, 
is based on the measure of D'. Each diamond indicates the pairwise mag-
nitude of LD, with dark grey indicating strong LD (D' > 0.8) and a log-
arithm of odds score of greater than 2.0. Single nucleotide polymorphisms 
(SNPs) < 5% for this ethnic group not shown. (Figure prepared with 
LocusView, Broad Institute, Cambridge, MA, unpublished software by T. 
Petryshen, A. Kirby, and M. Ainscow [61]).
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Additional file 7
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) 
locus for African-Americans. The horizontal black line depicts the 210-
kilobase region of chromosome (chr) 5 analyzed in our multiethnic panel. 
The PRLR gene is shown in grey (RefSeq gene = completed genes from the 
human genome assembly). Alternative first exons are shown in black 
below the gene: hE13, hE1N1, hE1N2, hE1N3, hE1N4, and hE1N5. 
The LD plot, presented at the bottom of the figures, is based on the meas-
ure of D'. Each diamond indicates the pairwise magnitude of LD, with 
dark grey indicating strong LD (D' > 0.8) and a logarithm of odds score 
of greater than 2.0. Single nucleotide polymorphisms (SNPs) < 5% for 
this ethnic group not shown. (Figure prepared with LocusView, Broad 
Institute, Cambridge, MA, unpublished software by T. Petryshen, A. 
Kirby, and M. Ainscow [61]).
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[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-72-S7.png]
Additional file 8
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) 
locus for Native-Hawaiians. The horizontal black line depicts the 210-
kilobase region of chromosome (chr) 5 analyzed in our multiethnic panel. 
The PRLR gene is shown in grey (RefSeq gene = completed genes from the 
human genome assembly). Alternative first exons are shown in black 
below the gene: hE13, hE1N1, hE1N2, hE1N3, hE1N4, and hE1N5. 
The LD plot, presented at the bottom of the figures, is based on the meas-
ure of D'. Each diamond indicates the pairwise magnitude of LD, with 
dark grey indicating strong LD (D' > 0.8) and a logarithm of odds score 
of greater than 2.0. Single nucleotide polymorphisms (SNPs) < 5% for 
this ethnic group not shown. (Figure prepared with LocusView, Broad 
Institute, Cambridge, MA, unpublished software by T. Petryshen, A. 
Kirby, and M. Ainscow [61]).
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[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-72-S8.png]
Additional file 9
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) 
locus for Japanese-Americans. The horizontal black line depicts the 210-
kilobase region of chromosome (chr) 5 analyzed in our multiethnic panel. 
The PRLR gene is shown in grey (RefSeq gene = completed genes from the 
human genome assembly). Alternative first exons are shown in black 
below the gene: hE13, hE1N1, hE1N2, hE1N3, hE1N4, and hE1N5. 
The LD plot, presented at the bottom of the figures, is based on the meas-
ure of D'. Each diamond indicates the pairwise magnitude of LD, with 
dark grey indicating strong LD (D' > 0.8) and a logarithm of odds score 
of greater than 2.0. Single nucleotide polymorphisms (SNPs) < 5% for 
this ethnic group not shown. (Figure prepared with LocusView, Broad 
Institute, Cambridge, MA, unpublished software by T. Petryshen, A. 
Kirby, and M. Ainscow [61]).
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2350-8-72-S9.png]
Additional file 10
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) 
locus for Latinas. The horizontal black line depicts the 210-kilobase region 
of chromosome (chr) 5 analyzed in our multiethnic panel. The PRLR gene 
is shown in grey (RefSeq gene = completed genes from the human genome 
assembly). Alternative first exons are shown in black below the gene: 
hE13, hE1N1, hE1N2, hE1N3, hE1N4, and hE1N5. The LD plot, pre-
sented at the bottom of the figures, is based on the measure of D'. Each 
diamond indicates the pairwise magnitude of LD, with dark grey indicat-
ing strong LD (D' > 0.8) and a logarithm of odds score of greater than 
2.0. Single nucleotide polymorphisms (SNPs) < 5% for this ethnic group 
not shown. (Figure prepared with LocusView, Broad Institute, Cam-
bridge, MA, unpublished software by T. Petryshen, A. Kirby, and M. Ains-
cow [61]).
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2350-8-72-S10.png]
Additional file 11
Linkage disequilibrium (LD) plot across the prolactin receptor (PRLR) 
locus for Whites. The horizontal black line depicts the 210-kilobase region 
of chromosome (chr) 5 analyzed in our multiethnic panel. The PRLR gene 
is shown in grey (RefSeq gene = completed genes from the human genome 
assembly). Alternative first exons are shown in black below the gene: 
hE13, hE1N1, hE1N2, hE1N3, hE1N4, and hE1N5. The LD plot, pre-
sented at the bottom of the figures, is based on the measure of D'. Each 
diamond indicates the pairwise magnitude of LD, with dark grey indicat-
ing strong LD (D' > 0.8) and a logarithm of odds score of greater than 
2.0. Single nucleotide polymorphisms (SNPs) < 5% for this ethnic group 
not shown. (Figure prepared with LocusView, Broad Institute, Cam-
bridge, MA, unpublished software by T. Petryshen, A. Kirby, and M. Ains-
cow [61]).
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